Content about Specialty Pharmacy

NEW BRUNSWICK, N.J. — Johnson & Johnson's sales increased by 8.5% to $17.5 billion in first quarter 2013, the healthcare products company said Tuesday.

The increase included a domestic sales increase of 11.2%. Profits for the quarter were $3.5 billion.

SILVER SPRING, Md. — Two Dallas-based compounding pharmacies announced a recall of sterile drug products made at their facilities due to production conditions that could lead to contamination.

The Food and Drug Administration said Tuesday that ApotheCure had recalled all sterile drug products made at its pharmacy, while NuVision Pharmacy had recalled sterile freeze-dried or lyophilized drug products made at its facility. Both recalls were described as voluntary.

SILVER SPRING, Md. — An inspection of more than two-dozen compounding pharmacies by Food and Drug Administration officials has found widespread problems with sanitation and sterilization practices, FDA commissioner Margaret Hamburg wrote in a blog post on the agency's website Thursday.

WASHINGTON — Legislation designed to limit the use of biosimilars has met defeat in Maryland.

TAMPA, Fla. — The National Association of Specialty Pharmacy has named James Smeeding its first executive director, the group said Tuesday. The announcement was made during its first Specialty Pharmacy Conference in San Diego, which drew more than 500 participants.

Smeeding is the founder of the University of Texas College of Pharmacy's Center for Pharmacoeconomic studies and has worked for a variety of companies and organizations, including the TPG National Payor Roundtable, the Jestarx Group, Digital Health Dialog and others.

ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy will notify physicians within two hours whether a patient has been accepted for treatment, the company said.

BioPlus said the new "2-Hour Patient Acceptance Guarantee" program would let physicians know if their patients could be admitted pending insurance qualifications or would not be admitted and triaged to another pharmacy.

NEW YORK — A joint conference by the National Association of Specialty Pharmacy and the Association of Managed Care Pharmacy attracted hundreds of leaders from across the specialty pharmacy industry.

LONDON — GlaxoSmithKline has started a late-stage clinical trial of a drug in patients with an inflammatory disease that affects the blood vessels.

The drug maker announced the start of a phase-3 trial of Benlysta (belimumab) in patients with vasculitis, a condition in which the body's immune system attacks blood vessels, leading to inflammation, disruption of blood flow and possible damage to the organs. The drug is being tested in patients with a common form of the disease known as anti-neutrophil cytoplasmic antibodies-positive vasculitis.

HYDERABAD, India — Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis' Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.

WASHINGTON — A committee of Florida's state Senate has passed a bill that could limit the use of biosimilars in the state.

The Florida Senate Committee on Health Policy passed S.B. 732, sending it to the full state senate. The legislation would require pharmacists to inform doctors when a follow-on biologic was substituted for a brand-name biotech drug. The bill is similar to one signed into law last month by Virginia Gov. Bob McDonnell.

LISLE, Ill. — Washington-based accrediting organization URAC has accredited pharmacy benefit manager Catamaran Corp.'s specialty pharmacy brand, Catamaran said.

The PBM said BriovaRx had been awarded URAC's Specialty Pharmacy Accreditation. Catamaran said URAC offered the only third-party, voluntary accreditation program of this scope for the pharmacy benefit management and prescription services industry.